• Pioglitazone and the PPARγ Axis: Strategic Insights for T...

  2025-10-02

  This thought-leadership article explores the mechanistic and translational potential of Pioglitazone, a selective PPARγ agonist, in modulating immune-metabolic pathways central to type 2 diabetes mellitus, inflammatory disorders, and neurodegeneration. Blending rigorous mechanistic insight with strategic guidance, it contextualizes recent breakthroughs in macrophage polarization, highlights experimental best practices, and delivers a forward-looking perspective for researchers aiming to bridge preclinical discovery with clinical relevance.

• SR-202: Selective PPARγ Antagonist for Next-Generation Im...

  2025-10-01

  Explore how SR-202, a selective PPARγ antagonist, advances immunometabolic research by enabling precise inhibition of PPAR-dependent adipocyte differentiation and modulation of macrophage polarization. This in-depth analysis uncovers novel insights for insulin resistance and anti-obesity drug development.

• Pioglitazone and PPARγ: Advanced Modulation in Inflammati...

  2025-09-30

  Explore how pioglitazone, a selective PPARγ agonist, advances research into inflammatory process modulation and macrophage polarization beyond metabolic studies. This article uniquely dissects STAT-1/STAT-6 pathways, offering new scientific insights for type 2 diabetes mellitus research and immune regulation.

• SR-202 (PPAR Antagonist): Precision Tools for Unraveling ...

  2025-09-29

  Discover how SR-202, a selective PPARγ antagonist, enables advanced mechanistic studies in nuclear receptor inhibition, immune-metabolic crosstalk, and therapeutic development for obesity and type 2 diabetes. Explore novel angles in PPAR-dependent adipocyte differentiation inhibition and macrophage polarization research.

• Canagliflozin Hemihydrate: Next-Generation SGLT2 Inhibito...

  2025-09-28

  Explore how Canagliflozin hemihydrate, a leading SGLT2 inhibitor, uniquely empowers glucose metabolism and diabetes mellitus research. This article reveals its advanced utility in mechanistic pathway discovery, setting it apart from traditional approaches.

• Pioglitazone: Unraveling PPARγ Signaling and Immune Modul...

  2025-09-27

  Explore the multifaceted utility of Pioglitazone as a PPARγ agonist in pioneering research on insulin resistance, macrophage polarization, and neuroinflammation. This article uniquely integrates mechanistic depth with recent findings on immune modulation, offering advanced insights beyond traditional metabolic applications.

• SR-202: A Selective PPARγ Antagonist for Targeted Nuclear...

  2025-09-26

  Explore the unique properties of SR-202, a selective PPARγ antagonist, and its advanced applications in insulin resistance and anti-obesity drug development. This article provides in-depth mechanistic insights and comparative analysis, distinct from existing reviews.

• Pioglitazone and PPARγ: Advanced Mechanisms in Immune-Met...

  2025-09-25

  Explore the advanced mechanisms by which Pioglitazone, a potent PPARγ agonist, modulates immune-metabolic pathways in type 2 diabetes mellitus research, beta cell protection, and inflammatory process modulation. This article offers a distinctive, in-depth analysis of STAT-1/STAT-6 signaling and neuroprotection, setting it apart from existing reviews.

• Canagliflozin Hemihydrate: Advanced Experimental Strategi...

  2025-09-24

  Explore Canagliflozin hemihydrate as a high-purity SGLT2 inhibitor for advanced glucose metabolism research. This article uniquely integrates recent pathway specificity findings and experimental design insights to elevate metabolic disorder studies.

• Pioglitazone as a PPARγ Agonist: Novel Insights into Macr...

  2025-09-23

  Explore the role of Pioglitazone, a selective PPARγ agonist, in modulating macrophage polarization and attenuating inflammatory processes in disease models. This article presents recent mechanistic findings and practical guidance for leveraging Pioglitazone in type 2 diabetes mellitus and neuroinflammation research.

• WY-14643 (Pirinixic Acid): Modulating PPAR Signaling in T...

  2025-09-22

  WY-14643 (Pirinixic A

• SR-202: A Selective PPARγ Antagonist for Immunometabolic ...

  2025-09-19

  SR-202, a selective PPARγ antagonist, is advancing immunometabolic research by enabling precise inhibition of PPAR-dependent adipocyte differentiation and modulation of macrophage polarization. This article explores SR-202’s mechanistic role in insulin resistance, obesity, and immune signaling pathways, with a focus on its unique utility in dissecting PPARγ functions.

• SR-202: Advancing Insulin Resistance and Obesity Research...

  2025-09-18

  Explore how SR-202, a selective PPARγ antagonist, enables precise investigations of nuclear receptor inhibition in insulin resistance, obesity, and inflammation models. Learn how SR-202 drives innovation in PPAR-dependent adipocyte differentiation inhibition and translational metabolic research.

• Caspase-4 Colorimetric Assay Kit synthesis About this report

  2025-03-03

  

  About this report 2018 Alzheimer's Disease Facts and Figures is a statistical resource for U.S. data related to Alzheimer's disease, the most common cause of dementia. Background and context for interpreting the data are contained in the Overview. Additional sections address prevalence, mortality a

• OCT also is known as POU F plays an

  2025-03-03

  

  OCT4 (also is known as POU5F1) plays an important role in embryonic stem cell self-renewal, development and reprogram somatic cell into pluripotent stem cell [[5], [6], [7]]. Recently, many studies also find OCT4 promotes the progression of many tumors. For example, Wnt/β-catenin promotes the expans

14455 records 1/964 page Next 12345 下5页 Last page